Tag Archives: Pharmaceutical industry

Biopharmaceutical Innovation Hubs and the Future of Work

Posted on June 25, 2015 by

Innovation hubs such as metro Boston are all the rage.  Urban living is back in style, face-to-face communication trounces teleconferences, and innovation-starved pharma companies are looking to academic centers for new targets and new enabling technologies.  Academic institutions in turn are looking … Continue reading →

Posted in Boston-Cambridge, Economics, Innovation | Tagged , , | Leave a comment

Bristol Meyers Squibb Joins the R&D Hub Consolidation in Cambridge, Massachusetts

Posted on June 25, 2015 by

BMS has just announced that it will be closing its Wallingford, Connecticut facility and relocating much of R&D to Cambridge MA.  Derek Lowe has some coverage.

Posted in Pharmaceutical Industry | Tagged , , , | Leave a comment

China crackdowns squeeze pharma margins

Posted on May 25, 2014 by

From Reuters: A crackdown on corruption and pricing in China’s fast-growing pharmaceutical market has squeezed profits and margins, raising a red flag to global Big Pharma that the days of easy growth in the country may be over. Over the … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , | Leave a comment

Who’s The Best In Drug Research? 22 Companies Ranked Incorrectly

Posted on May 23, 2014 by

Matt Herper at Forbes has a post on new pharmaceutical research productivity data from Richard Evans, a former Roche executive and Wall Street analyst.  Evans calculates metrics such as (1) Economic Returns to R&D spending, (2) Patents / $1M R&D spend, (3) Average … Continue reading →

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , | Leave a comment

Pfizer is a shark that can’t stop feeding

Posted on May 8, 2014 by

So says John LaMattina, a former head of research at Pfizer: The only way for a shark to survive is to keep going forward. To maintain its leadership, Pfizer will again need to make a major acquisition in the next … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , | Leave a comment

Consolidation in the Pharma industry continues unabated

Posted on May 6, 2014 by

As large assets swaps, mergers and acquisitions continue in the Pharma industry, Merck has announced it is selling its Consumer Care division to Bayer for $14B. The transaction will move Bayer into second place in consumer care, behind J&J. Merck … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , | Leave a comment

Pharma companies consider selling off mature drug portfolios

Posted on May 5, 2014 by

As big shifts in the Pharmaceutical industry continue, Reuters is reporting that several large pharma companies, including Abbott, Merck and Sanofi, are considering selling off their portfolios of compounds that have lost patent protection.  From a pharma company’s perspective, branded … Continue reading →

Posted in Pharmaceutical Industry | Tagged , | 1 Comment

Pharma megamergers — against the spirit of the times?

Posted on April 23, 2014 by

Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday.  As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading →

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , , , , , | 1 Comment

Pharma deal frenzy points to fundamental change in strategy

Posted on April 23, 2014 by

Pharmaceutical giants Novartis and GSK announced a large swap in business units on Tuesday, resulting in both companies becoming significantly more specialized — reversing their decades-long traditional strategies of greater diversification across product lines. The Wall Street Journal has more than … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , , | 1 Comment

Infographic: Top 15 Large Pharma Companies by Market Cap

Posted on April 17, 2014 by

Interesting chart of the top 15 large pharma & biotech firms ranked by market capitalization.  Note the resemblance to a power-law distribution (or exponential, really).  If business outcomes are distributed like this, why would employee performance be normally distributed? Data from … Continue reading →

Image | Posted on April 17, 2014 by | Tagged , , | Leave a comment